Sustained Release Injectable Market by Type and Application- Global Industry Analysis & Forecast to 2027

Published On : January 2021 Pages : 158 Category: Chemicals & Nanomaterials Report Code : CM0215381

Sustained Release Injectable Market by Type(Exenatide,Naltrexone,Estradiol)Application (Leukemia,Diabetes,Acromegaly)- Global Industry Analysis & Forecast to 2027

Industry Outlook and Trend Analysis

Sustained Release Injectable Market has encountered significant development over the recent years and is anticipated to grow tremendously over the forecast period.Health and nutritional benefits have been linked with nutraceutical ingredients obtained from oral dietary components extracted from them. These ingredients have shown considerable potential for anti-aging effects in recent decades by impeding or slowing skin cell degradation. 

Drivers and Restraints

Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for company, regions segments, type segments and applications (end users). In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.

Regional Insights

The data for 2021 is an estimate, based on the history data and the integrated view of industry experts, manufacturers, distributors and end users etc.

By Region

  • North America
    • S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia-Pacific
  • SouthAmerica
    • Brazil
    • Argentina
    • Columbia
    • Rest of South America
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Egypt
    • Nigeria
    • South Africa
    • Rest of MEA

Competitive Analysis                         

The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

  • Eli Lilly
  • AstraZeneca
  • Critical Pharmaceuticals
  • Sanofi
  • Novartis
  • Roche
  • Aurobindo
  • Biomarin
  • Avadel
  • Camurus
  • Alkermes

Some of the key questions answered by the report are:

  • What was the market size in 2017 and forecast from 2021 to 2027?
  • What will be the industry market growth from 2017 to 2027?
  • What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
  • What are the major segments leading the market growth and why?
  • Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?

Market Classification

·         Sustained Release Injectable Market, ByType, Estimates and Forecast, 2017-2027 ($Million)

o    Exenatide

o    Naltrexone

o    Estradiol

·         Sustained Release Injectable Market, ByApplication, Estimates and Forecast, 2017-2027 ($Million)

o    Leukemia

o    Diabetes

o    Acromegaly

·         Sustained Release Injectable Market, By Key Players, Estimates and Forecast, 2017-2027 ($Million)

o    Eli Lilly

o    AstraZeneca

o    Critical Pharmaceuticals

o    Sanofi

o    Novartis

o    Roche

o    Aurobindo

o    Biomarin

o    Avadel

o    Camurus

o    Alkermes

·         Sustained Release Injectable Market, By Region, Estimates and Forecast, 2017-2027 ($Million)

o    North America

§  North America Sustained Release Injectable Market, By Country

o    U.S. Sustained Release Injectable Market

o    Canada Sustained Release Injectable Market

o    Mexico Sustained Release Injectable Market

o    Europe

§  Europe Sustained Release Injectable Market, By Country

·         Germany Sustained Release Injectable Market

o    UK Sustained Release Injectable Market

o    France Sustained Release Injectable Market

o    RussiaSustained Release Injectable Market

o    Italy Sustained Release Injectable Market

o    Rest of Europe Sustained Release Injectable Market

o    Asia-Pacific

§  Asia-Pacific Sustained Release Injectable Market, By Country

o    ChinaSustained Release Injectable Market

o    Japan Sustained Release Injectable Market

o    South KoreaSustained Release Injectable Market

o    India Sustained Release Injectable Market

o    Southeast AsiaSustained Release Injectable Market

o    Rest of Asia-Pacific Sustained Release Injectable Market

o    South America

§  South AmericaSustained Release Injectable Market

o    Brazil Sustained Release Injectable Market

o    ArgentinaSustained Release Injectable Market

o    ColumbiaSustained Release Injectable Market

o    Rest of South America Sustained Release Injectable Market

o    Middle East and Africa

§  Middle East and AfricaSustained Release Injectable Market

o    Saudi ArabiaSustained Release Injectable Market

o    UAESustained Release Injectable Market

o    EgyptSustained Release Injectable Market

o    NigeriaSustained Release Injectable Market

o    South Africa Sustained Release Injectable Market

o    Rest of MEA Sustained Release Injectable Market

Table of Contents:

1.       Introduction

1.1.     Report Description

2.       Executive Summary

2.1.     Key Highlights

3.       Market Overview

3.1.     Introduction

3.1.1.  Market Definition

3.1.2.  Market Segmentation

3.2.     Market Dynamics

3.2.1.  Drivers

3.2.2.  Restraints

3.2.3.  Opportunities

4.       Market Analysis by Regions

4.1.     North America (United States, Canada and Mexico)

4.1.1.  United States Market Status and Outlook (2017-2027)

4.1.2.  Canada Market Status and Outlook (2017-2027)

4.1.3.  Mexico Market Status and Outlook (2017-2027)

4.2.     Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

4.2.1.  Germany Market Status and Outlook (2017-2027)

4.2.2.  France Market Status and Outlook (2017-2027)

4.2.3.  UK Market Status and Outlook (2017-2027)

4.2.4.  Russia Market Status and Outlook (2017-2027)

4.2.5.  Italy Market Status and Outlook (2017-2027)

4.2.6.  Rest of Europe Market Status and Outlook (2017-2027)

4.3.     Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Rest of Asia-Pacific)

4.3.1.  China Market Status and Outlook (2017-2027)

4.3.2.  Japan Market Status and Outlook (2017-2027)

4.3.3.  Korea Market Status and Outlook (2017-2027)

4.3.4.  India Market Status and Outlook (2017-2027)

4.3.5.  Southeast Asia Market Status and Outlook (2017-2027)

4.3.6.  Rest of Asia-Pacific Market Status and Outlook (2017-2027)

4.4.     South America (Brazil, Argentina, Columbia and Rest of South America)

4.4.1.  Brazil Market Status and Outlook (2017-2027)

4.4.2.  Argentina Market Status and Outlook (2017-2027)

4.4.3.  Columbia Market Status and Outlook (2017-2027)

4.4.4.  Rest of South America Market Status and Outlook (2017-2027)

4.5.     Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa and Rest of MEA)

4.5.1.  Saudi Arabia Market Status and Outlook (2017-2027)

4.5.2.  United Arab Emirates Market Status and Outlook (2017-2027)

4.5.3.  Egypt Market Status and Outlook (2017-2027)

4.5.4.  Nigeria Market Status and Outlook (2017-2027)

4.5.5.  South Africa Market Status and Outlook (2017-2027)

4.5.6.  Turkey Market Status and Outlook (2017-2027)

4.5.7.  Rest of Middle East and Africa Market Status and Outlook (2017-2027)

5.       Sustained Release Injectable Market, By Type

5.1.     Introduction

5.2.     Global Sustained Release Injectable Revenue and Market Share by Type (2017-2021)

5.2.1.  Global Sustained Release Injectable Revenue and Revenue Share by Type (2017-2021)

5.3.     Exenatide

5.3.1.  Global Exenatide Revenue and Growth Rate (2017-2021)

5.4.     Naltrexone

5.4.1.  Global Naltrexone Revenue and Growth Rate (2017-2021)

5.5.     Estradiol

5.5.1.  Global Estradiol Revenue and Growth Rate (2017-2021)

6.       Sustained Release Injectable Market, By Application

6.1.     Introduction

6.2.     Global Sustained Release Injectable Revenue and Market Share by Application (2017-2021)

6.2.1.  Global Sustained Release Injectable Revenue and Revenue Share by Application (2017-2021)

6.3.     Leukemia

6.3.1.  Global Leukemia Revenue and Growth Rate (2017-2021)

6.4.     Diabetes

6.4.1.  Global Diabetes Revenue and Growth Rate (2017-2021)

6.5.     Acromegaly

6.5.1.  Global Acromegaly Revenue and Growth Rate (2017-2021)

7.       Sustained Release Injectable Market, By Region

7.1.     Introduction

7.2.     Global Sustained Release Injectable Revenue and Market Share by Regions

7.2.1.  Global Sustained Release Injectable Revenue by Regions (2017-2021)

7.3.     North America Sustained Release Injectable by Countries

7.3.1.  North America Sustained Release Injectable Revenue and Growth Rate (2017-2021)

7.3.2.  North America Sustained Release Injectable Revenue (Million USD) by Countries (2017-2021)

7.3.3.  United States

7.3.3.1.  United States Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.3.4.  Canada

7.3.4.1.  Canada Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.3.5.  Mexico

7.3.5.1.  Mexico Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.     Europe Sustained Release Injectable by Countries

7.4.1.  Europe Sustained Release Injectable Revenue and Growth Rate (2017-2021)

7.4.2.  Europe Sustained Release Injectable Revenue (Million USD) by Countries (2017-2021)

7.4.3.  Germany

7.4.3.1.  Germany Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.4.  France

7.4.4.1.  France Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.5.  UK

7.4.5.1.  UK Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.6.  Russia

7.4.6.1.  Russia Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.7.  Italy

7.4.7.1.  Italy Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.4.8.  Rest of Europe

7.4.8.1.  Rest of Europe Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.     Asia-Pacific Sustained Release Injectable by Countries

7.5.1.  Asia-Pacific Sustained Release Injectable Revenue and Growth Rate (2017-2021)

7.5.2.  Asia-Pacific Sustained Release Injectable Revenue (Million USD) by Countries (2017-2021)

7.5.3.  China

7.5.3.1.  China Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.4.  Japan

7.5.4.1.  Japan Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.5.  Korea

7.5.5.1.  Korea Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.6.  India

7.5.6.1.  India Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.7.  Southeast Asia

7.5.7.1.  Southeast Asia Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.5.8.  Rest of Asia-Pacific

7.5.8.1.  Rest of Asia-Pacific Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.6.     South America Sustained Release Injectable by Countries

7.6.1.  South America Sustained Release Injectable Revenue and Growth Rate (2017-2021)

7.6.2.  South America Sustained Release Injectable Revenue (Million USD) by Countries (2017-2021)

7.6.3.  Brazil

7.6.3.1.  Brazil Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.6.4.  Argentina

7.6.4.1.  Argentina Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.6.5.  Columbia

7.6.5.1.  Columbia Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.6.6.  Rest of South America

7.6.6.1.  Rest of South America Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.     Middle East and Africa Sustained Release Injectable by Countries

7.7.1.  Middle East and Africa Sustained Release Injectable Revenue and Growth Rate (2017-2021)

7.7.2.  Middle East and Africa Sustained Release Injectable Revenue (Million USD) by Countries (2017-2021)

7.7.3.  Saudi Arabia

7.7.3.1.  Saudi Arabia Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.4.  United Arab Emirates

7.7.4.1.  United Arab Emirates Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.5.  Egypt

7.7.5.1.  Egypt Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.6.  Nigeria

7.7.6.1.  Nigeria Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.7.  South Africa

7.7.7.1.  South Africa Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.8.  Turkey

7.7.8.1.  Turkey Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

7.7.9.  Rest of Middle East and Africa

7.7.9.1.  Rest of Middle East and Africa Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2021)

8.       Company Profiles

8.1.     Eli Lilly

8.1.1.  Business Overview

8.1.2.   Service Portfolio

8.1.3.  Strategic Developments

8.1.4.  Financial Overview

8.2.     AstraZeneca

8.2.1.  Business Overview

8.2.2.   Service Portfolio

8.2.3.  Strategic Developments

8.2.4.  Financial Overview

8.3.     Critical Pharmaceuticals

8.3.1.  Business Overview

8.3.2.   Service Portfolio

8.3.3.  Strategic Developments

8.3.4.  Financial Overview

8.4.     Sanofi

8.4.1.  Business Overview

8.4.2.   Service Portfolio

8.4.3.  Strategic Developments

8.4.4.  Financial Overview

8.5.     Novartis

8.5.1.  Business Overview

8.5.2.   Service Portfolio

8.5.3.  Strategic Developments

8.5.4.  Financial Overview

8.6.     Roche

8.6.1.  Business Overview

8.6.2.   Service Portfolio

8.6.3.  Strategic Developments

8.6.4.  Financial Overview

8.7.     Aurobindo

8.7.1.  Business Overview

8.7.2.   Service Portfolio

8.7.3.  Strategic Developments

8.7.4.  Financial Overview

8.8.     Biomarin

8.8.1.  Business Overview

8.8.2.   Service Portfolio

8.8.3.  Strategic Developments

8.8.4.  Financial Overview

8.9.     Avadel

8.9.1.  Business Overview

8.9.2.   Service Portfolio

8.9.3.  Strategic Developments

8.9.4.  Financial Overview

8.10. Camurus

8.10.1.      Business Overview

8.10.2.       Service Portfolio

8.10.3.      Strategic Developments

8.10.4.      Financial Overview

8.11. Alkermes

8.11.1.      Business Overview

8.11.2.       Service Portfolio

8.11.3.      Strategic Developments

8.11.4.      Financial Overview

9.       Sustained Release Injectable Market Forecast (2022-2027)

9.1.     Global Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2022-2027)

9.2.     Sustained Release Injectable Market Forecast by Regions (2022-2027)

9.2.1.  North America Sustained Release Injectable Market Forecast (2022-2027)

9.2.1.1.  United States Sustained Release Injectable Market Forecast (2022-2027)

9.2.1.2.  Canada Sustained Release Injectable Market Forecast (2022-2027)

9.2.1.3.  Mexico Sustained Release Injectable Market Forecast (2022-2027)

9.2.2.  Europe Sustained Release Injectable Market Forecast (2022-2027)

9.2.2.1.  Germany Sustained Release Injectable Market Forecast (2022-2027)

9.2.2.2.  France Sustained Release Injectable Market Forecast (2022-2027)

9.2.2.3.  UK Sustained Release Injectable Market Forecast (2022-2027)

9.2.2.4.  Russia Sustained Release Injectable Market Forecast (2022-2027)

9.2.2.5.  Italy Sustained Release Injectable Market Forecast (2022-2027)

9.2.2.6.  Rest of Europe Sustained Release Injectable Market Forecast (2022-2027)

9.2.3.  Asia-Pacific Sustained Release Injectable Market Forecast (2022-2027)

9.2.3.1.  China Sustained Release Injectable Market Forecast (2022-2027)

9.2.3.2.  Japan Sustained Release Injectable Market Forecast (2022-2027)

9.2.3.3.  Korea Sustained Release Injectable Market Forecast (2022-2027)

9.2.3.4.  India Sustained Release Injectable Market Forecast (2022-2027)

9.2.3.5.  Southeast Asia Sustained Release Injectable Market Forecast (2022-2027)

9.2.3.6.  Rest of Asia-Pacific Sustained Release Injectable Market Forecast (2022-2027)

9.2.4.  South America Sustained Release Injectable Market Forecast (2022-2027)

9.2.4.1.  Brazil Sustained Release Injectable Market Forecast (2022-2027)

9.2.4.2.  Argentina Sustained Release Injectable Market Forecast (2022-2027)

9.2.4.3.  Columbia Sustained Release Injectable Market Forecast (2022-2027)

9.2.4.4.  Rest of South America Sustained Release Injectable Market Forecast (2022-2027)

9.2.5.  Middle East and Africa Sustained Release Injectable Market Forecast (2022-2027)

9.2.5.1.  Saudi Arabia Sustained Release Injectable Market Forecast (2022-2027)

9.2.5.2.  United Arab Emirates Sustained Release Injectable Market Forecast (2022-2027)

9.2.5.3.  Egypt Sustained Release Injectable Market Forecast (2022-2027)

9.2.5.4.  Nigeria Sustained Release Injectable Market Forecast (2022-2027)

9.2.5.5.  South Africa Sustained Release Injectable Market Forecast (2022-2027)

9.2.5.6.  Turkey Sustained Release Injectable Market Forecast (2022-2027)

9.2.5.7.  Rest of Middle East and Africa Sustained Release Injectable Market Forecast (2022-2027)

9.3.     Sustained Release Injectable Market Forecast by Type (2022-2027)

9.3.1.  Sustained Release Injectable Forecast by Type (2022-2027)

9.3.2.  Sustained Release Injectable Market Share Forecast by Type (2022-2027)

9.4.     Sustained Release Injectable Market Forecast by Application (2022-2027)

9.4.1.  Sustained Release Injectable Forecast by Application (2022-2027)

9.4.2.  Sustained Release Injectable Market Share Forecast by Application (2022-2027)


List of Tables

List of Tables and Figures:

Figure United States Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Canada Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Mexico Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Germany Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure France Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure UK Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Russia Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Italy Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Europe Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure China Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Japan Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Korea Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure India Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Southeast Asia Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Asia-Pacific Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Brazil Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Argentina Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Columbia Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of South America Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Saudi Arabia Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure United Arab Emirates Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Egypt Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Nigeria Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure South Africa Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Turkey Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Figure Rest of Middle East and Africa Sustained Release Injectable Revenue (Million USD) and Growth Rate (2017-2027)
Table Global Sustained Release Injectable Revenue and Revenue Share by Type (2017-2019)
Figure Global Exenatide Revenue and Growth Rate (2017-2019)
Figure Global Naltrexone Revenue and Growth Rate (2017-2019)
Figure Global Estradiol Revenue and Growth Rate (2017-2019)
Table Global Sustained Release Injectable Revenue and Revenue Share by Application (2017-2019)
Figure Global Leukemia Revenue and Growth Rate (2017-2019)
Figure Global Diabetes Revenue and Growth Rate (2017-2019)
Figure Global Acromegaly Revenue and Growth Rate (2017-2019)
Table Global Sustained Release Injectable Revenue by Regions (2017-2019)
Figure North America Sustained Release Injectable Growth Rate (2017-2019)
Figure North America Sustained Release Injectable Revenue and Growth Rate (2017-2019)
Figure North America Sustained Release Injectable by Countries (2017-2019)
Figure North America Sustained Release Injectable Revenue (Million USD) by Countries (2017-2019)
Figure United States Sustained Release Injectable Growth Rate (2017-2019)
Figure United States Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Canada Sustained Release Injectable Growth Rate (2017-2019)
Figure Canada Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Mexico Sustained Release Injectable Growth Rate (2017-2019)
Figure Mexico Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Europe Sustained Release Injectable Growth Rate (2017-2019)
Figure Europe Sustained Release Injectable Revenue and Growth Rate (2017-2019)
Figure Europe Sustained Release Injectable by Countries (2017-2019)
Figure Europe Sustained Release Injectable Revenue (Million USD) by Countries (2017-2019)
Figure Germany Sustained Release Injectable Growth Rate (2017-2019)
Figure Germany Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure France Sustained Release Injectable Growth Rate (2017-2019)
Figure France Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure UK Sustained Release Injectable Growth Rate (2017-2019)
Figure UK Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Russia Sustained Release Injectable Growth Rate (2017-2019)
Figure Russia Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Italy Sustained Release Injectable Growth Rate (2017-2019)
Figure Italy Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Europe Sustained Release Injectable Growth Rate (2017-2019)
Figure Rest of Europe Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Asia-Pacific Sustained Release Injectable Growth Rate (2017-2019)
Figure Asia-Pacific Sustained Release Injectable Revenue and Growth Rate (2017-2019)
Figure Asia-Pacific Sustained Release Injectable by Countries (2017-2019)
Figure Asia-Pacific Sustained Release Injectable Revenue (Million USD) by Countries (2017-2019)
Figure China Sustained Release Injectable Growth Rate (2017-2019)
Figure China Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Japan Sustained Release Injectable Growth Rate (2017-2019)
Figure Japan Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Korea Sustained Release Injectable Growth Rate (2017-2019)
Figure Korea Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure India Sustained Release Injectable Growth Rate (2017-2019)
Figure India Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Southeast Asia Sustained Release Injectable Growth Rate (2017-2019)
Figure Southeast Asia Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Sustained Release Injectable Growth Rate (2017-2019)
Figure Rest of Asia-Pacific Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South America Sustained Release Injectable Growth Rate (2017-2019)
Figure South America Sustained Release Injectable Revenue and Growth Rate (2017-2019)
Figure South America Sustained Release Injectable by Countries (2017-2019)
Figure South America Sustained Release Injectable Revenue (Million USD) by Countries (2017-2019)
Figure Brazil Sustained Release Injectable Growth Rate (2017-2019)
Figure Brazil Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Argentina Sustained Release Injectable Growth Rate (2017-2019)
Figure Argentina Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Columbia Sustained Release Injectable Growth Rate (2017-2019)
Figure Columbia Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of South America Sustained Release Injectable Growth Rate (2017-2019)
Figure Rest of South America Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Middle East and Africa Sustained Release Injectable Growth Rate (2017-2019)
Figure Middle East and Africa Sustained Release Injectable Revenue and Growth Rate (2017-2019)
Figure Middle East and Africa Sustained Release Injectable by Countries (2017-2019)
Figure Middle East and Africa Sustained Release Injectable Revenue (Million USD) by Countries (2017-2019)
Figure Saudi Arabia Sustained Release Injectable Growth Rate (2017-2019)
Figure Saudi Arabia Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure United Arab Emirates Sustained Release Injectable Growth Rate (2017-2019)
Figure United Arab Emirates Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Egypt Sustained Release Injectable Growth Rate (2017-2019)
Figure Egypt Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Nigeria Sustained Release Injectable Growth Rate (2017-2019)
Figure Nigeria Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure South Africa Sustained Release Injectable Growth Rate (2017-2019)
Figure South Africa Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Turkey Sustained Release Injectable Growth Rate (2017-2019)
Figure Turkey Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Sustained Release Injectable Growth Rate (2017-2019)
Figure Rest of Middle East and Africa Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2017-2019)
Table Eli Lilly Sustained Release Injectable Financial Overview
Table AstraZeneca Sustained Release Injectable Financial Overview
Table Critical Pharmaceuticals Sustained Release Injectable Financial Overview
Table Sanofi Sustained Release Injectable Financial Overview
Table Novartis Sustained Release Injectable Financial Overview
Table Roche Sustained Release Injectable Financial Overview
Table Aurobindo Sustained Release Injectable Financial Overview
Table Biomarin Sustained Release Injectable Financial Overview
Table Avadel Sustained Release Injectable Financial Overview
Table Camurus Sustained Release Injectable Financial Overview
Table Alkermes Sustained Release Injectable Financial Overview
Figure Global Sustained Release Injectable Revenue (Millions USD) and Growth Rate (2019-2027)
Table Sustained Release Injectable Market Forecast by Regions (2019-2027)
Figure North America Sustained Release Injectable Market Forecast (2019-2027)
Figure United States Sustained Release Injectable Market Forecast (2019-2027)
Figure Canada Sustained Release Injectable Market Forecast (2019-2027)
Figure Mexico Sustained Release Injectable Market Forecast (2019-2027)
Figure Europe Sustained Release Injectable Market Forecast (2019-2027)
Figure Germany Sustained Release Injectable Market Forecast (2019-2027)
Figure France Sustained Release Injectable Market Forecast (2019-2027)
Figure UK Sustained Release Injectable Market Forecast (2019-2027)
Figure Russia Sustained Release Injectable Market Forecast (2019-2027)
Figure Italy Sustained Release Injectable Market Forecast (2019-2027)
Figure Rest of Europe Sustained Release Injectable Market Forecast (2019-2027)
Figure Asia-Pacific Sustained Release Injectable Market Forecast (2019-2027)
Figure China Sustained Release Injectable Market Forecast (2019-2027)
Figure Japan Sustained Release Injectable Market Forecast (2019-2027)
Figure Korea Sustained Release Injectable Market Forecast (2019-2027)
Figure India Sustained Release Injectable Market Forecast (2019-2027)
Figure Southeast Asia Sustained Release Injectable Market Forecast (2019-2027)
Figure Rest of Asia-Pacific Sustained Release Injectable Market Forecast (2019-2027)
Figure South America Sustained Release Injectable Market Forecast (2019-2027)
Figure Brazil Sustained Release Injectable Market Forecast (2019-2027)
Figure Argentina Sustained Release Injectable Market Forecast (2019-2027)
Figure Columbia Sustained Release Injectable Market Forecast (2019-2027)
Figure Rest of South America Sustained Release Injectable Market Forecast (2019-2027)
Figure Middle East and Africa Sustained Release Injectable Market Forecast (2019-2027)
Figure Saudi Arabia Sustained Release Injectable Market Forecast (2019-2027)
Figure United Arab Emirates Sustained Release Injectable Market Forecast (2019-2027)
Figure Egypt Sustained Release Injectable Market Forecast (2019-2027)
Figure Nigeria Sustained Release Injectable Market Forecast (2019-2027)
Figure South Africa Sustained Release Injectable Market Forecast (2019-2027)
Figure Turkey Sustained Release Injectable Market Forecast (2019-2027)
Figure Rest of Middle East and Africa Sustained Release Injectable Market Forecast (2019-2027)
Figure Global Sustained Release Injectable Forecast by Type (2019-2027)
Figure Global Sustained Release Injectable Market Share Forecast by Type (2019-2027)
Figure Global Sustained Release Injectable Forecast by Type (2019-2027)
Figure Global Sustained Release Injectable Forecast by Application (2019-2027)
Figure Global Sustained Release Injectable Market Share Forecast by Application (2019-2027)
Figure Global Sustained Release Injectable Forecast by Application (2019-2027)

Please Note: Data related to the Companies are subject to Availability.


Research Methodology

We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

Data Mining

Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.

Data Collection Matrix

Data Collection Matrix

Supply Side

Demand Side

Primary Data Sources

  • Manufacturers
  • Distributors & Wholesalers
  • GPOs
  • Physicians/Specialist
  • Healthcare Providers
  • Consumers

Secondary Data Sources

  • Annual Reports/SEC Filings/ Investor Presentations/ Press Releases
  • Government/Associations Publications
  • Case Studies
  • Reference Customers

 

Market Modeling and Forecasting

We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.

  • Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
  • Number of patients for particular device or medical procedure and
  • Repeated use of particular device depending on health and condition of patient
  • Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.

We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.

Data Validation

We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.

Data Triangulation

data triangulation

Industry Analysis

Qualitative Data

Quantitative Data (2017-2025)

  • Market Dynamics (Drivers, Restraints, and Challenges)
  • Industry Trend Analysis
  • Market Opportunities
  • Government Policies and Regulations, Patent Analysis, and Reimbursement Policies
  • Porter’s Five Forces and PESTLE Analysis
  • Key Developments and Competitive Landscape
  • Market Assessment and Forecast
  • Market Assessment and Forecast, By Product
  • Market Assessment and Forecast, By Technology
  • Market Assessment and Forecast, By Application
  • Market Assessment and Forecast, By End User
  • Market Assessment and Forecast, By Region/Country

License Type

For Any Assistance

*
*
*
*
*